Document is current
Any future updates will be listed below
-
Authors
Jiang, Zehua
Xu, Yueyuan
Lim, Zhi Wei
Wang, Ziyao
Han, Yingxiang
Yew, Samantha Min Er
Pan, Zhe
Wang, Qian https://orcid.org/0000-0001-5246-3611
Wu, Gangyue
Wong, Tien Yin https://orcid.org/0000-0002-8448-1264
Wang, Xiaofei https://orcid.org/0000-0002-3175-0344
Wang, Yaxing https://orcid.org/0000-0003-2749-7793
Tham, Yih Chung https://orcid.org/0000-0002-6752-797X
- License Information
-
More Information
Article History
Received: 28 August 2024
Revised: 12 March 2025
Accepted: 20 March 2025
First Online: 13 April 2025
Competing interests
: TYW discloses receiving consulting fees from multiple pharmaceutical companies including Aldropika Therapeutics, Bayer, Boehringer Ingelheim, Genentech, Iveric Bio, Novartis, Plano, Oxurion, Roche, Sanofi, Shanghai Henlius. Additionally, TYW holds roles as an inventor, patent holder, and co-founder of the start-up companies EyRiS and Visre. The remaining authors have reported no conflicts of interest.
